

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Napp Pharmaceuticals (bendamustine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Cancer 52 • Cancer Black Care • Cancer Equality • Counsel and Care • Equalities National Council • Helen Rollason Heal Cancer Charity • Leukaemia CARE • Leukaemia Society (UK) • Lymphoma Association • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • Rarer Cancers Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association for Services to the Elderly • British Blood Transfusion Society • British Committee for Standardisation in Haematology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Blood and Bone Marrow Transplantation • British Society for Haematology • Cancer Networks Pharmacists Forum 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Health Care Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Service for Wales • Scottish Medicines Consortium <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> • Accord Healthcare (doxorubicin) • Actavis UK (prednisolone, fludarabine) • Alliance Pharmaceuticals (prednisolone) • Arrow Generics (prednisolone) • Baxter Healthcare (cyclophosphamide) • Co-Pharma (prednisolone) • Genzyme (fludarabine) • Hameln Pharmaceuticals (doxorubicin, dexamethasone) • Hospira UK (doxorubicin, fludarabine, dexamethasone) • Janssen-Cilag (doxorubicin) • Medac UK (doxorubicin) • Pfizer (cyclophosphamide, doxorubicin, prednisolone) • Roche Products (rituximab) • Teva UK (doxorubicin, fludarabine) • Wockhardt UK (doxorubicin, prednisolone,

National Institute for Health and Clinical Excellence

Provisional matrix for the technology appraisal of bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Cancer Research UK • National Blood Service • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiology • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Bath & North East Somerset, and Wiltshire PCT Cluster • Department of Health • Southampton, Hampshire, Isle of Wight & Portsmouth PCT Cluster • Welsh Assembly Government 	<p>fludarabine)</p> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Elimination of Leukaemia Fund • Institute of Cancer Research • Leukaemia & Lymphoma Research • Leukaemia Busters • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute of the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme • Southampton Health Technology Assessment Centre (SHTAC), University of Southampton <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence

Provisional matrix for the technology appraisal of bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence

Provisional matrix for the technology appraisal of bendamustine in combination with rituximab for the first-line treatment of mantle cell lymphoma